Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Pharma Deals, Investments and M&As in September 2017
In our continuous endeavor to share business intelligence that can help grow your pharmaceutical bus
